Results 161 to 170 of about 46,290 (201)

Potent immune-dependent anticancer effects of the non-cardiotoxic anthracycline aclarubicin. [PDF]

Oncoimmunology
Cerrato G, Sauvat A, Abdellatif M, Kroemer G.   +3 more
europepmc   +1 more source

Current strategies for prevention of cancer therapy-related cardiotoxicity: pharmacological, non-pharmacological and emerging approaches. [PDF]

Front Cardiovasc Med
Migliari M, Fazzini L, Campana N, Deidda M, Dessì M, Cadeddu Dessalvi C.   +5 more
europepmc   +1 more source

Cardiotoxicity in Breast Cancer Therapy: Risks, Mechanisms, and Prevention Strategies. [PDF]

Med Sci (Basel)
Fitrianti AE, Wardani NO, Astuti A, Anggadiredja K, Amalia L, Putri RA, Zazuli Z.   +6 more
europepmc   +1 more source

Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines: A Randomized Clinical Trial.

JAMA Netw Open
Xia C, Smith AM, Lefebvre B, Jamal FA, Armenian SH, Koropeckyj-Cox D, Zhang L, Liu PP, Landsburg D, Clark AS, Shah PD, Hubbard RA, Huang A, Golec S, Hewitt M, Wilcox NS, Chen Z, Rethy L, Jung W, Ko K, Narayan V, Martei YM, Lang NN, Januzzi JL, Felker GM, Ky B.   +25 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Anthracyclines

2005
Abstract Daunorubicin was the first anthracycline isolated, in France and Italy simultaneously in 1963, from the fermentation broth of an actinobacteria Streptomyces peucetius, and its antileukaemic properties in the clinic were rapidly acknowledged.
David, Hamilton, Gerald, Batist
  +6 more sources

Anthracycline resistance

Acta Oncologica, 1989
The major limitation of the usefulness of anthracyclines is the development of drug resistance. Most of the data related to anthracycline resistance has been obtained in experimental animal tumors or in cultured human cell lines. An important characteristic obtained in these models is the common finding of cross-resistance to a series of drugs ...
Bhushan, Alok, Kermode, John C., Posada, James, Tritton, Thomas R.   +3 more
openaire   +4 more sources

Anthracyclines

International Journal of Oncology, 1996
The genotoxicity and carcinogenicity data from in vitro and in vivo studies conducted during preclinical safety assessment of doxorubicin (DOXO), epirubicin (EPI) and idarubicin (IDA), are reviewed. The genotoxicity assays included a) gene mutation in Salmonella typhimurium with 5 tester strains; b) gene mutation in the V79 mammalian (lung) cell line ...
G, Mazue, G, Williams, M, Iatropoulos, A, Newman, U, Sammartini, R, Pulci, S, Castellino, G, Scampini, M, Brughera, A, Imondi, A, Podesta   +10 more
openaire   +2 more sources

Anthracycline cardiotoxicity

Expert Opinion on Drug Safety, 2011
Anthracyclines are widely prescribed anticancer agents that cause a dose-related cardiotoxicity, often aggravated by nonanthracycline chemotherapeutics or new generation targeted drugs. Anthracycline cardiotoxicity may occur anytime in the life of cancer survivors.
Pierantonio, Menna, Odalys Gonzalez, Paz, Massimo, Chello, Elvio, Covino, Emanuela, Salvatorelli, Giorgio, Minotti   +5 more
openaire   +2 more sources

Anthracycline cardiotoxicity

Expert Opinion on Drug Safety, 2006
The use of anthracyclines is limited by dose-dependent cardiotoxicity. Three forms of anthracycline cardiotoxicity are described; an immediate pericarditis-myocarditis syndrome, an early onset chronic progressive CHF developing during or shortly after therapy and late-onset cardiotoxicity presenting years following treatment.
Robin L, Jones, Charles, Swanton, Michael S, Ewer   +2 more
openaire   +2 more sources